- Home
- EMPD vs NTRB Comparison
EMPD vs NTRB Comparison
Compare EMPD & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMPD | NTRB |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 72.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EMPD | NTRB |
|---|---|---|
| Price | $3.20 | $8.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 294.5K | 130.6K |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $974,977.00 | ★ $2,036,651.00 |
| Revenue This Year | $23.49 | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.48 | $2.80 |
| 52 Week High | $8.10 | $9.19 |
Technical Indicators
Market Signals| Indicator | EMPD | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 63.88 |
| Support Level | $2.77 | $3.68 |
| Resistance Level | $3.22 | N/A |
| Average True Range (ATR) | 0.16 | 0.97 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 76.84 | 67.79 |
Price Performance
Historical ComparisonAbout EMPD Empery Digital Inc.
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.